Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Asan Medical Center
With
Title: Combining 90Y-Ibritumomab tiuxetan (Zevalin) with high-dose chemotherapy of BuCyE and autologous stem cell transplantation in patients with relapsed, refractory, or high-risk B-cell non-Hodgkin's lymphoma - an open-labeled phase II study. Study design: Prospective, multicenter, open-labeled, phase II trial. Study objectives: * Primary: event-free survival time following autologous stem cell transplantation with 90Y-Ibritumomab tiuxetan and BuCyE high-dose chemotherapy in patients with relapsed, refractory, or high-risk B-cell non-Hodgkin's lymphoma * Secondary: overall survival response rate toxicity of the treatment combination Treatment: Z-BuCyE Regimen * Day 21: rituximab, 250 mg/m2, I.V. * Day 14: rituximab, 250 mg/m2, I.V. 90Y-Ibritumomab tiuxetan, 0.4 mCi/kg, I.V. * Day 7, 6, 5: busulfan 3.2 mg/kg I.V. * Day 5, 4: etoposide 200 mg/m2 I.V. every 12 hours * Day 3, 2: Cytoxan 50 mg/kg I.V. * Day 0: autologous stem cell infusion
Age
0–64
Sex
ALL
Healthy volunteers
Not accepted